Early clinical case studies
Discover how our expertise and innovative solutions have successfully advanced clinical trials and drug development.
With extensive medical and operational experience, we deliver seamless execution in both healthy volunteer and patient cohort studies, providing critical safety and tolerability data in the early clinical stages of development.
Accelerated enrolment in a lactation study
ICON exceeded enrolment expectations in a competitive lactation research environment, completing enrolment more than twice as fast as planned while achieving 100% participant completion through a convenient, participant-centric study design.
Proactive problem-solving preserves data integrity in lactation study
ICON rapidly resolved a critical sample stability issue, preserving data integrity while enrolling 8 participants and achieving 100% completion.
Lactation study of an FcRn inhibitor
ICON's targeted recruitment strategy accelerated enrolment, minimised screen failures, achieved 100% completion, and ensured timely study delivery.
Lactation study for two CGRP receptor therapies
ICON overcame complex recruitment barriers through targeted outreach and flexible scheduling, achieving full enrolment, 100% retention, and on-time delivery.
Complex oral semaglutide lactation study
Rapid recruitment and participant-focused support enabled ICON to restore study momentum, reduce risk, and achieve full completion in this rescue study.
Delivering high quality data in a complex heart failure trial
CardioResearch and ICON partnered to deliver a complex phase 1b–2a heart failure trial through collaborative expertise, governance, and innovative operational execution.
Solving complexity in early clinical imaging
ICON partnered with the University Medical Center Groningen to deliver a complex crossover study with 240 brain MRIs in 60 participants, delivering fast, consistent data and a seamless experience.
ADME and ABA trial in solid tumor patients
This phase 1 oncology ADME and ABA study faced strict eligibility, screening, radiolabeled drug logistics, and 72-hour shelf-life constraints, requiring precise coordination, specialised expertise and patient recruitment.
Recruitment success in a challenging phase 1 osteoporosis biosimilar study
Successful 3-arm, double-blind study on a denosumab biosimilar in 225 healthy men over 10 months at two ICON sites.
Global coordination for phase 1 success
A pharma client partnered with ICON to support EU and US approval of a new diabetes therapy. ICON’s Manufacturing & Pharmacy Services team sourced, labeled, and shipped comparator and study drugs for a complex phase 1 trial, helping meet the sponsor’s accelerated timeline.
Overcoming enrollment challenges in an early phase obesity trial
A large pharma company partnered with ICON to conduct a phase 1 obesity study assessing the safety and tolerability of a new investigational oral amycretin therapy.
Complex phase 1 obesity study
ICON was once again selected as a partner to conduct a phase 1 study in individuals who are overweight or have obesity, evaluating the safety and tolerability of a new subcutaneous GLP-1 and amylin peptide formulation.